Search

Search Constraints

You searched for: Author/Creator Lutfi, Forat

Search Results

2. Severe dysautonomia as a manifestation of neurotoxicity after CAR‐T cell therapy for diffuse large B‐cell lymphoma. Issue 6 (8th April 2020)

3. The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma. (9th September 2021)

4. Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma. (10th November 2020)

5. The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma. (9th September 2021)

6. Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. Issue 6 (12th May 2022)

7. Immune effector cell–associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Issue 1 (5th August 2020)

8. C-reactive protein: not always a reliable marker of ongoing cytokine release syndrome in CAR-T therapy following IL-6 blockade. Issue 9 (28th July 2020)

10. Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. Issue 2 (28th January 2023)